Report Overview

The cardiovascular drug market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The burden of Non-Communicable Diseases (NCDs), including cardiovascular diseases is significant in Kenya. According to the World Heart Federation, Heart Diseases cause 25% of the hospital admissions and account for 13% of all hospital deaths in Kenya. The number is expected to increase in coming decade due to rapid urbanization, growth in ageing population and changing lifestyles. In addition, 13% of Kenyans consume alcohol and tobacco products daily and 94% eat less than five servings of fruits and vegetables per day. A large proportion of Kenyas urban population live in slums with poor housing and inadequate services. With an estimated 50 cardiologists for 44 million people, excessive shortage of specialists in the country add to the barriers to prevention, management and treatment of cardiovascular diseases.

Market Drivers

The market is majorly driven by the rising burden of cardiovascular diseases. Cardiovascular diseases (CVD) comprise 80% of non-communicable disease (NCD) burden in low- and middle-income countries and are increasingly impacting the poor inequitably. The risk factors include alcohol and tobacco consumption, smoking, sedentary lifestyle, increased dietary intake with saturated fats, stress, obesity and diabetes.

One of the crucial reasons of expansion of cardiovascular drug market is increased awareness of cardiac health among urban population and launch of new products propel the growth of the market. Many key players have come up with advanced drugs to treat cardiovascular diseases. For instance, introduction of drug Eliquis by Pfizer.inc.

Technological Advancements and the need for better and efficient drugs has also led to growth in the cardiovascular Drugs market.

Stringent Government regulations and side effects of the drugs are restraining market growth. Decline in the number of cardiac surgeries and hospital admissions because of lockdown measures due to the COVID-19 outbreak may also hamper the growth of cardiovascular drug market.